1. Medtech Insight
  2. >>Business

Change At Helm As Tissue Regenix Enters Next Growth Phase

 
• By Tina Tan

Regenerative medicine firm Tissue Regenix is now seeking a new CEO following the departure of Anthony Odell. The change in leadership comes two months after the company made its maiden M&A deal, acquiring CellRight Technologies.

Anthony Odell, who has been leading Tissue Regenix Group PLC for nearly a decade, is stepping down as CEO. His departure, announced Oct. 18, comes two months after he oversaw the closing of the regenerative medicine firm's acquisition of CellRight Technologies LLC (CRT), a young Texas start-up specializing in bone regeneration. (Also see "'Profitable, High-Growth' CellRight Bulks Up Tissue Regenix's Ortho Biz" - Medtech Insight, 20 July, 2017.).

Leeds, UK-based Tissue Regeneix told Medtech Insight that Odell had left with the agreement of the board of directors "as the business is moving into a new phase of development."...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.